CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses. Lucid Cap ...

CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actu ...

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may be blocked from proceeding if an ad-blocker is enabled [1]

Revenue and Sales Performance - Total revenue increased by 12.1%, or approximately $1.4 million, for the three months ended September 30, 2025, compared to the same period in 2024[75]. - Surgical Aesthetics segment sales increased 19.1%, or approximately $1.8 million, for the three months ended September 30, 2025, driven by the commercial launch of AYON and increased sales of single-use handpieces[75]. - OEM segment sales decreased 17.6%, or approximately $0.4 million, for the three months ended September 30, 2025, due to lower sales volume to existing customers[75]. - Surgical Aesthetics sales increased 8.0%, or approximately $2.1 million, for the nine months ended September 30, 2025, compared to the same period in 2024[76]. - OEM segment sales decreased 31.4%, or approximately $2.3 million, for the nine months ended September 30, 2025, due to decreased sales volume to existing customers[76]. Profitability and Margins - Gross profit for the three months ended September 30, 2025, increased 19.3% to $8.3 million, with a gross margin of 64.4% compared to 60.5% for the same period in 2024[78]. - Gross profit for the nine months ended September 30, 2025, increased 3.2% to $21.0 million, with a gross margin of 62.5% compared to 60.2% in the prior year[80]. Cost Management and Expenses - The company reduced its workforce by nearly 25% in November 2024, estimating annualized future cost savings of approximately $4.3 million[69]. - The company plans to reduce annual operating expenses below $40 million in 2025 through various cost-saving measures[69]. - Research and development expenses decreased 38.7% for the nine months ended September 30, 2025, totaling $2.4 million, primarily due to lower compensation and benefits costs[82]. - Professional services expense decreased 14.4% for the nine months ended September 30, 2025, amounting to $4.6 million, driven by reductions in physician and marketing consulting expenses[84]. - Salaries and related expenses decreased 27.5% for the nine months ended September 30, 2025, totaling $9.3 million, due to lower headcount and stock-based compensation[86]. - Selling, general and administrative expenses decreased 20.3% for the nine months ended September 30, 2025, amounting to $11.2 million, primarily due to lower travel and meeting costs[89]. Cash Flow and Financial Position - At September 30, 2025, cash and cash equivalents were approximately $25.1 million, down from $31.7 million at December 31, 2024[93]. - Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $5.5 million, a decrease from $15.5 million in the prior year[94]. - The company had purchase commitments totaling approximately $4.4 million, expected to be purchased within the next twelve months[101]. Compliance and Risk Management - As of September 30, 2025, the company was in compliance with the financial covenants of the Perceptive Credit Agreement, which includes revenue targets for the Surgical Aesthetics segment[98]. - The company has adjusted its accounts receivable allowance due to economic uncertainty in the capital equipment market, particularly in the aesthetic space, resulting in extended credit terms granted to customers[104]. - The company maintains a reserve for uncollectible accounts receivable, analyzing historical bad debt experience and the composition of outstanding receivables[104]. - There are no off-balance sheet arrangements currently in place[106]. - The company has not identified any changes in internal control over financial reporting that materially affect its operations[111]. - The management's disclosure controls and procedures were deemed effective as of September 30, 2025[110]. - There have been no material changes to the risk factors previously described in the Annual Report for the fiscal year ended December 31, 2024[115]. - The company has recorded liabilities for litigation contingencies when a loss is known or considered probable, requiring significant judgment[105]. - The company has not reported any unregistered sales of equity securities or defaults upon senior securities[116][117]. - The company has not disclosed any new products, technologies, market expansions, or acquisitions in the current report[108]. - There are no significant quantitative or qualitative disclosures about market risk applicable to the company[109]. Product Development - The AYON Body Contouring System™ received 510(k) clearance from the FDA on May 13, 2025, and the commercial launch commenced in September 2025[66].

Apyx Medical (NasdaqGS:APYX) Q3 2025 Earnings Call November 06, 2025 08:00 AM ET Company ParticipantsJeremy Feffer - Managing Director and Relationship ManagerMatt Hill - CFOCharlie Goodwin - CEOConference Call ParticipantsAlex Fuhrman - Managing Director and Equity Research AnalystDave Turkaly - Research AnalystMatt Hewitt - Senior Research AnalystSam Eiber - VP and Equity Research AnalystOperatorGood morning, ladies and gentlemen, and welcome to the Apyx Medical Third Quarter 2025 earnings conference call ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 increased by 12% to $12.9 million compared to $11.5 million in the same period last year [5][16] - Gross profit for Q3 2025 increased to $8.3 million, with a gross profit margin of 64.4%, up from 60.5% in the prior year [17][19] - Net loss attributable to stockholders decreased to $2 million, or $0.05 per share, compared to $4.7 million, or $0.14 per share in the prior year [19] Business Line Data and Key Metrics Changes - Revenue from the Surgical Aesthetics segment increased by 19% to $11.1 million, driven by the AYON Body Contouring System launch and increased sales of single-use handpieces [5][16] - OEM revenue decreased by 18% to $1.8 million, attributed to reduced sales volumes to existing customers [7][17] Market Data and Key Metrics Changes - Domestic revenue increased by 20% year-over-year to $9.3 million, while international revenue decreased by 4% to $3.5 million [17] - The company noted that the medical device industry typically experiences seasonality, with revenue trends generally lowest in the first and third quarters [17] Company Strategy and Development Direction - The company announced the rebranding of its Advanced Energy segment to Surgical Aesthetics to better align with its mission and product offerings [5] - The focus has shifted towards the Surgical Aesthetics segment, particularly the AYON launch, which is seen as the future of the company [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the market's response to AYON, highlighting strong pre-sales and initial deliveries [6][15] - The company anticipates continued growth driven by the increasing adoption of GLP-1 medications, which create a demand for body contouring solutions [12][34] Other Important Information - The company has successfully reduced operating expenses to $9.1 million for Q3 2025, down from $10.6 million in the prior year [18] - Cash used in operating activities decreased to $3.5 million for Q3 2025, compared to $4.4 million in the prior year [19][20] Summary of Q&A Session Question: Clarification on generator sales decline - Management clarified that the decline in generator sales is due to customers integrating existing generators with AYON, rather than purchasing new generators [25][26] Question: Gross margin impact and future guidance - Management refrained from providing specific guidance on gross margins but indicated that the Surgical Aesthetics business typically has the highest gross margins [27][29] Question: Expectations for consumables uptake - Management noted that the greatest driver of consumable sales will come from new customers adopting Renuvion technology [32] Question: Market demand trends and GLP-1 dynamics - Management stated that the market is being disrupted by GLP-1 drugs, with a significant percentage of patients being new to aesthetics [34][35] Question: Growth in single-use handpieces - Management indicated that growth in handpieces is driven by new doctors adopting the technology and higher attach rates for Renuvion [39] Question: Pipeline growth and installation processes - Management confirmed an increase in guidance for Surgical Aesthetics and highlighted the effective management of supply chain and installations [45][46] Question: International rollout of AYON - Management discussed plans for international registration of AYON, with a focus on Europe and other regions in the future [48][49]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 increased by 12% to $12.9 million compared to $11.5 million in the same period last year [5][14] - Gross profit for Q3 2025 increased to $8.3 million, with a gross profit margin of 64.4%, up from 60.5% in the prior year [15][17] - Net loss attributable to stockholders decreased to $2 million, or $0.05 per share, compared to $4.7 million, or $0.14 per share in the prior year [17] - Cash used in operating activities decreased to $3.5 million from $4.4 million in the prior year [17][18] Business Line Data and Key Metrics Changes - Revenue from the surgical aesthetics segment increased by 19% to $11.1 million, driven by the commercial launch of the Aon body contouring system [5][14] - OEM revenue decreased by 18% to $1.8 million, attributed to reduced sales volumes to existing customers [6][15] Market Data and Key Metrics Changes - Domestic revenue increased by 20% year-over-year to $9.3 million, while international revenue decreased by 4% year-over-year to $3.5 million [15] - The market for aesthetic procedures is expected to grow significantly due to the increasing adoption of GLP-1 medications, with over 15 million people currently on these drugs in the U.S. [11][32] Company Strategy and Development Direction - The company announced a rebranding of its advanced energy segment to "surgical aesthetics" to better align with its mission and product offerings [5] - The Aon system is positioned as a comprehensive solution for body contouring, integrating multiple functions that address market needs [8][10] - The company plans to expand the Aon system internationally, targeting markets such as Europe and Latin America [43][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial launch of Aon, which has exceeded expectations in terms of market interest and pre-orders [12][19] - The company anticipates a strong future in the aesthetic market, particularly due to the impact of GLP-1 drugs on patient demand for body contouring solutions [11][32] Other Important Information - The company updated its 2025 revenue guidance to a range of $50.5 million to $52.5 million, reflecting strong performance in the surgical aesthetics segment [18][20] - Gross margins are expected to be approximately 61% for the year, with total operating expenses not exceeding $40 million [21] Q&A Session Summary Question: Clarification on generator sales decline - Management explained that the decline in generator sales is due to the integration of the Aon system, where existing customers can upgrade their generators instead of purchasing new ones [24] Question: Gross margin impact from Aon rollout - Management refrained from providing specific guidance on gross margins but indicated that the surgical aesthetics business typically has the highest gross margins [26] Question: Expected uptake in consumables alongside capital sales - Management noted that new customer acquisitions would drive consumable sales, while existing customers may not see significant increases [30] Question: Market environment and GLP-1 dynamics - Management highlighted that the market is being disrupted by GLP-1 drugs, with a significant percentage of patients being new to aesthetic treatments [32] Question: Growth in handpiece sales - Management indicated that growth in handpiece sales was driven by new doctor adoption, higher attach rates, and standalone uses of Renuvion technology [36] Question: Pipeline growth and implementation - Management confirmed an increase in guidance due to strong interest in Aon and mentioned that a third party is assisting with installations to meet demand [40][41] Question: International rollout of Aon - Management stated that while the focus is currently on the U.S. market, plans for international registration and rollout are in consideration for 2026 [43][44]

Apyx Medical Corporation Reports Third Quarter 2025 Financial Results CLEARWATER, FL — November 6, 2025 - Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended September 30, 2025. Recent Financial and Operating Highlights: "In September, we successfully transitioned the commercialization program for AYON from an effective soft ...

Core Insights - Apyx Medical Corporation reported a 19% increase in Surgical Aesthetics revenue for Q3 2025, driven by the successful commercialization of the AYON Body Contouring System [3][9] - The company anticipates further growth in sales following the pending FDA clearance for the AYON's label expansion to include power liposuction [4][7] - Total revenue for Q3 2025 reached $12.9 million, a 12.1% increase compared to $11.5 million in the same period last year [7][9] Financial Performance - Surgical Aesthetics revenue for Q3 2025 was $11.1 million, up from $9.3 million in Q3 2024, reflecting a 19% increase [9][10] - OEM revenue decreased by 18% to approximately $1.8 million in Q3 2025 compared to $2.2 million in Q3 2024 [7][9] - Gross profit for Q3 2025 increased to $8.3 million, with a gross margin of 64.4%, up from 60.5% in the prior year [10][12] Operating Expenses and Losses - Operating expenses decreased by $1.5 million to $9.1 million in Q3 2025 compared to $10.6 million in Q3 2024 [11] - Net loss attributable to stockholders was $2.0 million in Q3 2025, an improvement from a net loss of $4.7 million in Q3 2024 [12][24] - Adjusted EBITDA loss decreased significantly to $0.1 million for Q3 2025, compared to $2.4 million for the same period in 2024 [13][31] Future Outlook - The company raised its total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million, up from the previous guidance of $50.0 million to $52.0 million [6][20] - Surgical Aesthetics revenue is expected to be between $43.0 million and $45.0 million for FY2025, compared to approximately $38.6 million reported for FY2024 [20] - The company plans to continue expanding the user base for AYON, which is expected to drive growth in single-use handpiece sales [4][6]

Core Insights - Apyx Medical Corporation is set to participate in two upcoming investor conferences, showcasing its proprietary technologies [1][2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion and the AYON Body Contouring System™ [3] - Renuvion and J-Plasma technologies provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The AYON Body Contouring System™ is an FDA-cleared platform that integrates multiple capabilities for comprehensive body contouring treatments [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]